Katherine A. Hoadley
#144,986
Most Influential Person Now
American breast cancer researcher
Katherine A. Hoadley's AcademicInfluence.com Rankings
Katherine A. Hoadleylaw Degrees
Law
#2988
World Rank
#3744
Historical Rank
#1259
USA Rank
Common Law
#175
World Rank
#189
Historical Rank
#27
USA Rank
Download Badge
Law
Katherine A. Hoadley's Degrees
- PhD Genetics and Molecular Biology University of North Carolina at Chapel Hill
- Bachelors Biology University of North Carolina at Chapel Hill
Similar Degrees You Can Earn
Why Is Katherine A. Hoadley Influential?
(Suggest an Edit or Addition)According to Wikipedia, Katherine A. Hoadley is an American breast cancer researcher. , she has served as the Associate Director of Cancer Genomics for the High-Throughput Sequencing Facility at UNC Lineberger Comprehensive Cancer Center. Her research is focused on understanding the biology of cancer through gene expression analyses and integrative genomic approaches.
Katherine A. Hoadley's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Comprehensive molecular portraits of human breast tumors (2012) (7791)
- Integrated Genomic Analyses of Ovarian Carcinoma (2011) (6411)
- Comprehensive molecular characterization of human colon and rectal cancer (2012) (6141)
- Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. (2010) (5816)
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways (2008) (5775)
- Comprehensive molecular profiling of lung adenocarcinoma (2014) (4095)
- Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. (2013) (3821)
- Integrated genomic characterization of endometrial carcinoma (2013) (3708)
- Comprehensive genomic characterization of squamous cell lung cancers (2012) (2998)
- Comprehensive genomic characterization of head and neck squamous cell carcinomas (2015) (2860)
- The Immune Landscape of Cancer (2018) (2766)
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. (2015) (2211)
- Genomic Classification of Cutaneous Melanoma (2015) (2143)
- Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. (2010) (2121)
- The Molecular Taxonomy of Primary Prostate Cancer (2015) (2116)
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014) (2007)
- Comprehensive molecular characterization of urothelial bladder carcinoma (2014) (1748)
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics (2018) (1745)
- Comprehensive molecular characterization of clear cell renal cell carcinoma (2013) (1724)
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
- Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma (2017) (1514)
- Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma (2016) (1474)
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (2017) (1446)
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
- Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer (2015) (1332)
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer (2018) (1329)
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma (2015) (1232)
- Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin (2014) (1192)
- Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. (2017) (1092)
- Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation (2018) (984)
- Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. (2016) (931)
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas (2016) (826)
- Integrated genomic and molecular characterization of cervical cancer (2017) (762)
- Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology (2014) (695)
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer (2012) (668)
- The chromatin accessibility landscape of primary human cancers (2018) (646)
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial (2018) (587)
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas (2017) (577)
- A Consensus Molecular Classification of Muscle-invasive Bladder Cancer (2018) (574)
- Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. (2017) (572)
- Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. (2012) (509)
- Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
- TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. (2012) (430)
- JOINT AND INDIVIDUAL VARIATION EXPLAINED (JIVE) FOR INTEGRATED ANALYSIS OF MULTIPLE DATA TYPES. (2011) (378)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. (2017) (371)
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA , IDH 1 , EGFR , and NF 1 Citation Verhaak (2010) (362)
- Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles (2017) (361)
- MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays. (2016) (354)
- Integrative Molecular Characterization of Malignant Pleural Mesothelioma. (2018) (340)
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. (2016) (301)
- Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. (2016) (295)
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (2018) (277)
- Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. (2018) (276)
- EGFR associated expression profiles vary with breast tumor subtype (2007) (273)
- Integrated Molecular Characterization of Testicular Germ Cell Tumors (2018) (261)
- Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set (2016) (260)
- Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer Genes (2013) (255)
- Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling (2014) (254)
- Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types (2010) (248)
- Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. (2016) (241)
- Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. (2016) (235)
- Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics (2018) (234)
- Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. (2018) (222)
- Genomic basis for RNA alterations in cancer (2020) (221)
- The Integrated Genomic Landscape of Thymic Epithelial Tumors. (2018) (210)
- Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer (2014) (198)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Proteogenomic Characterization of Endometrial Carcinoma (2020) (194)
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
- Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting (2016) (180)
- Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas (2017) (178)
- Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer (2004) (174)
- miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. (2012) (171)
- Tumor mutational burden is a determinant of immune-mediated survival in breast cancer (2018) (168)
- Gene expression patterns associated with p53 status in breast cancer (2006) (164)
- RNA expression analysis of formalin-fixed paraffin-embedded tumors (2007) (163)
- Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. (2015) (141)
- Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy (2015) (115)
- The molecular diversity of Luminal A breast tumors (2013) (114)
- A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns (2020) (113)
- Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer (2018) (111)
- Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. (2020) (105)
- Proteogenomic characterization of pancreatic ductal adenocarcinoma (2021) (101)
- In Vitro and In Vivo Analysis of B-Myb in Basal-Like Breast Cancer (2008) (96)
- Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study (2018) (93)
- Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases (2016) (92)
- An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer* (2015) (92)
- Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades (2017) (92)
- Erratum: Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles (Cell Reports (2017) 18(11) (2780–2794) (S2211124717302140) (10.1016/j.celrep.2017.02.033)) (2017) (88)
- Impact of Tumor Microenvironment and Epithelial Phenotypes on Metabolism in Breast Cancer (2012) (88)
- Before and After: Comparison of Legacy and Harmonized TCGA Genomic Data Commons' Data. (2019) (83)
- The molecular basis of breast cancer pathological phenotypes (2017) (82)
- A proteogenomic portrait of lung squamous cell carcinoma (2021) (77)
- An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer (2009) (76)
- Integrated RNA and DNA sequencing improves mutation detection in low purity tumors (2014) (75)
- Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy (2010) (71)
- Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification (2018) (70)
- Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR diagnosis (2007) (65)
- Prognostic value of B cells in cutaneous melanoma (2019) (62)
- Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. (2017) (61)
- Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. (2019) (58)
- Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer (2018) (58)
- Erratum: Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma (Cancer Cell (2016) 29(5) (723–736) (S153561081630160X) (10.1016/j.ccell.2016.04.002)) (2016) (54)
- The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy (2019) (53)
- FOXM1 Deubiquitination by USP21 Regulates Cell Cycle Progression and Paclitaxel Sensitivity in Basal-like Breast Cancer (2019) (53)
- Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. (2020) (48)
- Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer (2018) (48)
- Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status (2014) (47)
- Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis. (2016) (47)
- Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells (2017) (45)
- Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer (2018) (44)
- Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status. (2013) (42)
- Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer (2017) (42)
- Sex differences in oncogenic mutational processes (2019) (41)
- Potential Tumor Suppressor Role for the c-Myb Oncogene in Luminal Breast Cancer (2010) (41)
- Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. (2020) (38)
- An approach for normalization and quality control for NanoString RNA expression data (2020) (38)
- Prediction of Toxicant-Specific Gene Expression Signatures after Chemotherapeutic Treatment of Breast Cell Lines (2004) (36)
- Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma (2020) (36)
- DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas (2016) (35)
- High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations (2020) (34)
- Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer. (2019) (32)
- Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series (2019) (29)
- Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). (2014) (28)
- Genomic basis for RNA alterations revealed by whole-genome analyses of 27 cancer types (2017) (27)
- BreakTrans: uncovering the genomic architecture of gene fusions (2013) (26)
- CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer (2022) (26)
- Identification of mRNA isoform switching in breast cancer (2016) (26)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc (2015) (21)
- Nuclear Localized LSR: A Novel Regulator of Breast Cancer Behavior and Tumorigenesis (2016) (21)
- Genetic determinants of the molecular portraits of epithelial cancers (2019) (20)
- Tumor mutational landscape is a record of the pre-malignant state (2019) (20)
- Potential Predictive Markers of Benefit from Cetuximab in Metastatic Breast Cancer: An Analysis of Two Randomized Phase 2 Trials. (2009) (20)
- Erratum: Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes (PLoS ONE (2013) 8:7 DOI:10.1371/annotation/b42f61c5-cb7e-49ca-8cd6-6e1f7903ad08) (2013) (19)
- Molecular analysis of TCGA breast cancer histologic types (2021) (19)
- Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts (2019) (17)
- PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study Cohorts (2018) (16)
- Pan-cancer study of heterogeneous RNA aberrations (2017) (16)
- TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases (2018) (16)
- Virus expression detection reveals RNA-sequencing contamination in TCGA (2020) (16)
- Age at diagnosis, obesity, smoking, and molecular subtypes in muscle-invasive bladder cancer (2017) (15)
- Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas (2019) (14)
- Proteomic profiling of patient‐derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development (2015) (14)
- Abstract S6-01:BRCA1methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012) (2017) (14)
- Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer (2021) (14)
- The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma (2019) (11)
- Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway (2021) (10)
- Bidimensional linked matrix factorization for pan-omics pan-cancer analysis (2020) (10)
- Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression (2022) (9)
- National Cancer Institute Biospecimen Evidence-Based Practices: Harmonizing Procedures for Nucleic Acid Extraction from Formalin-Fixed, Paraffin-Embedded Tissue. (2018) (9)
- Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study (2017) (9)
- Correction: Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer Genes (2013) (8)
- SCISSOR: a framework for identifying structural changes in RNA transcripts (2021) (8)
- Correction: Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases (2017) (7)
- Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling (2014) (7)
- Abstract S2-04: Comprehensive molecular characterization of invasive lobular breast tumors (2015) (7)
- JOINT AND INDIVIDUAL ANALYSIS OF BREAST CANCER HISTOLOGIC IMAGES AND GENOMIC COVARIATES. (2019) (7)
- Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials. (2019) (6)
- Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features (2020) (6)
- The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer. (2015) (6)
- Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis (2022) (6)
- Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas. (2017) (5)
- Protein-based immune profiles of basal-like vs. luminal breast cancers (2020) (5)
- Title: Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically-important and correspond to different normal cell types (2010) (5)
- Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy. (2017) (5)
- Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer: A correlative analysis of the CALGB 40601 clinical trial (Alliance) (2019) (5)
- Genetic changes associated with relapse in favorable histology Wilms tumor: A Children’s Oncology Group AREN03B2 study (2022) (5)
- Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer (2015) (4)
- Ancestry-specific predisposing germline variants in cancer (2020) (4)
- In silico APC/C substrate discovery reveals cell cycle-dependent degradation of UHRF1 and other chromatin regulators (2020) (4)
- Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network (2020) (4)
- Morphological and molecular classification of human cancer (2017) (4)
- 162PDPathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification (TNBCtype-4) (2017) (3)
- Using RNA Sequencing to Characterize the Tumor Microenvironment. (2020) (3)
- Abstract 3703: A genomic characterization of testicular germ cell tumor immune microenvironment (2017) (3)
- Hepatocyte growth factor pathway expression in breast cancer by race and subtype (2021) (3)
- The landscape of immune microenvironments in racially-diverse breast cancer patients. (2022) (3)
- Correction: Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer Genes (2018) (3)
- Comparison of Breast CancerMolecular Features and Survival byAfrican and EuropeanAncestry in The Cancer GenomeAtlas (2017) (3)
- Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. (2022) (3)
- Abstract S4-02: A comprehensive analysis of fusion transcripts in breast cancer reveals associations between number of fusion transcripts, copy number events, gene expression profiles, and potentially clinical outcome (2016) (2)
- Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer (2023) (2)
- Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis. (2017) (2)
- 120MO Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials (2021) (2)
- RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer (2022) (2)
- Abstract SY12-03: Multi-tumor analysis of TCGA data identifies expression commonalities across tumor types. (2013) (2)
- In silico APC/C substrate discovery reveals cell cycle degradation of chromatin regulators including UHRF1 (2020) (2)
- Integrative modeling identifies genetic ancestry-associated molecular correlates in human cancer (2021) (2)
- Genomic characterization of rare molecular subclasses of hepatocellular carcinoma (2021) (2)
- TP 53 protein levels , RNA-based pathway assessment , and race among invasive breast cancer cases (2018) (2)
- A Pan-Cancer and Polygenic Bayesian Hierarchical Model for the Effect of Somatic Mutations on Survival (2019) (2)
- Abstract 2969: Progress in The Cancer Genome Atlas bladder cancer project (2015) (2)
- Abstract P4-05-03: Mutational analysis of triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) (2020) (2)
- UNMASC: tumor-only variant calling with unmatched normal controls (2021) (2)
- Pairwise Nonlinear Dependence Analysis of Genomic Data (2022) (1)
- Identification of targeted therapies for basal-like breast tumors (2006) (1)
- Race and Ancestry in Immune Response to Breast Cancer. (2022) (1)
- Comprehensive analysis of cancer stemness (2018) (1)
- DNA Damage Repair Classifier Defines Distinct Groups in Hepatocellular Carcinoma (2022) (1)
- Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway (2021) (1)
- Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases (2022) (1)
- Abstract SY10-02: Pan-cancer study of recurrent and heterogeneous RNA aberrations and association with whole-genome variants (2017) (1)
- Abstract PD7-02: Identification of breast cancers with an indolent disease course: 70 gene indolent threshold validation in a Swedish randomized trial of tamoxifen vs. not, with 20 year outcomes (2017) (1)
- Analytical protocol to identify local ancestry-associated molecular features in cancer (2021) (1)
- Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press. (2020) (1)
- SCISSOR: a framework for identifying structural changes in RNA transcripts (2021) (1)
- Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer (2022) (1)
- Comprehensive characterization of 412 muscle invasive urothelial carcinomas: Final analysis of The Cancer Genome Atlas (TCGA) project. (2016) (1)
- Abstract PD1-03: Multivariate analysis of subtype and gene expression signatures predictive of pathologic complete response (pCR) in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) (2017) (1)
- 787 The Cancer Genome Atlas (TCGA) project analysis of micro-RNA and gene expression subtypes of high-grade, muscle-invasive urothelial carcinoma (2016) (1)
- Abstract 3975: Detecting patient mutomes by integrating DNA and RNA sequencing (2012) (1)
- BreakTrans: uncovering the genomic architecture of gene fusions (2013) (1)
- Analysis of germline-driven ancestry-associated gene expression in cancers (2022) (1)
- Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns (2020) (1)
- Abstract S3-05: Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer (2017) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Biology of Human Tumors Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Speci fi c Breast and Ovarian Cancer (2014) (1)
- A hierarchical spike-and-slab model for pan-cancer survival using pan-omic data (2021) (1)
- Abstract PD8-03: ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer (2018) (1)
- Abstract 2976: Comprehensive Pan-Genomic characterization of adrenocortical carcinoma (2015) (1)
- Correction: Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy (2011) (1)
- Diffsig: Associating Risk Factors With Mutational Signatures (2023) (1)
- Comprehensive molecular profiling of urothelial bladder cancer at the DNA, RNA, and protein levels: A TCGA project. (2014) (1)
- Identification of drug targets for the treatment of Basal-like tumors (2005) (1)
- 186PBreast cancer PAM50 subtypes: Correlation between RNA-Seq and multiplexed gene expression platforms (2017) (1)
- A multi-omics longitudinal study of the murine retinal response to chronic low-dose irradiation and simulated microgravity (2022) (0)
- Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas (2019) (0)
- Abstract 2435A: Identification and treatment data of xenografts representing TCGA-defined glioblastoma subtypes (2015) (0)
- Abstract P3-16-01: Using the new pan-cancer clinical data resource (TCGA-CDR) to identify breast cancer genomic correlates associating with different survival outcome endpoints (2018) (0)
- Abstract 2727: The premalignant state captured in the landscape of somatic mutations can reveal the cancer cell-of-origin (2019) (0)
- Molecular Signatures of Drug Resistance (2009) (0)
- Jackstraw inference for AJIVE data integration (2021) (0)
- Abstract 987: Comprehensive characterization of urothelial bladder cancer: a TCGA Project update (2014) (0)
- Abstract PD18-04: Prognostic implications of PIK3CA mutation by hormone receptor status and intrinsic subtype in early stage HER2-positive breast cancer: a correlative analysis from CALGB 40601 (2023) (0)
- Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series (2019) (0)
- Abstract 128: Comprehensive molecular characterization of 412 muscle-invasive urothelial bladder carcinomas: final analysis of The Cancer Genome Atlas (TCGA) project (2016) (0)
- Evaluation of DNA repair biology signatures to predict specific carboplatin (C) versus docetaxel (D) benefit in advanced triple-negative breast cancer (aTNBC). (2020) (0)
- Impact of tumor and epithelial phenotypes on metabolism in breast cancer (2013) (0)
- Abstract S4-01: Identification of early versus late drivers of breast tumors and metastasis (2016) (0)
- Abstract PD9-03: Genomic analysis of the CALGB 40603 (Alliance) neoadjuvant trial in TNBC identifies immune features associated with pathological complete response and event-free survival (2021) (0)
- FFPE Sequencing and Bioinformatics. (2019) (0)
- Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells (2017) (0)
- Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study (2017) (0)
- A hierarchical spike-and-slab model for pan-cancer survival using pan-omic data (2022) (0)
- Integrative Genomic Analy sis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles Graphical (2017) (0)
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial (2018) (0)
- Abstract 2188: Urothelial cancer-GENOmic analysis to improve patient outcomes and research (UC-GENOME): a bladder cancer advocacy network (BCAN) led collaborative research study (2021) (0)
- Abstract 5895: Whole-genome characterization of lung adenocarcinomas lacking alterations in RTK/RAS/RAF/MAPK pathway (2020) (0)
- Impact of stromal microenvironment on metabolic phenotypes in breast cancer: evidence for stroma-influenced Warburg effect (2012) (0)
- Abstract PD8-01: Race and age differences in PAM50 biomarker status in the Carolina breast cancer study (2017) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- Virus expression detection reveals RNA-sequencing contamination in TCGA (2020) (0)
- TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study (2021) (0)
- Incorporating RNA-based Risk Scores for Genomic Instability to Predict Breast Cancer Recurrence and Immunogenicity in a Diverse Population (2022) (0)
- Abstract 1184: Association of immune microenvironment and race in the Carolina Breast Cancer Study (2020) (0)
- Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer (2011) (0)
- Abstract 876: TP53 pathway function, estrogen receptor status, and breast cancer risk factors in the Carolina Breast Cancer Study (2021) (0)
- Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression (2022) (0)
- Resource Reveals Molecular Classification Multiplatform Analysis of 12 Cancer Types within and across Tissues of Origin (0)
- Abstract LB-373: Comprehensive analysis of cancer stemness (2018) (0)
- Abstract PD2-03: Recurrent functionally diverse in-frameESR1gene fusions drive endocrine resistance in breast cancer (2017) (0)
- Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials. (2022) (0)
- Correction: Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer Genes (2014) (0)
- AB007. OS02.01. The integrated genomic landscape of thymic epithelial tumors: a report by the TCGA research network (2017) (0)
- Abstract 838: Establishment, identification and treatment data of TCGA glioblatoma xenograft subtypes (2014) (0)
- Abstract A039: The role of long noncoding RNAs in epithelial to mesenchymal transition and cancer stem cells (2013) (0)
- Measure of Strength of Evidence for Visually Observed Differences between Subpopulations (2021) (0)
- Non-Coding RNA modulate molecular subtype biology in muscle invasive bladder cancer (MIBC) and are independently associated with survival (2017) (0)
- Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases (2022) (0)
- Abstract SS1-05: Racial differences in breast cancer immune microenvironments (2021) (0)
- Abstract C045: Outcomes of hormone-receptor positive, HER2-negative breast cancers by race and tumor biologic features (2020) (0)
- Abstract 360: Thousands of published cancer signatures and pathways can be collapsed into a handful of non-redundant gene programs: a TCGA pan-cancer analysis (2014) (0)
- Abstract 1033: Estrogen receptor gene fusions drive endocrine therapy resistance in estrogen receptor positive breast cancer (2017) (0)
- Prognostic value of B cells in cutaneous melanoma (2019) (0)
- Additional file 1: Table S1. of Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy (2015) (0)
- Protein-based immune profiles of basal-like vs. luminal breast cancers. (2021) (0)
- Abstract PD9-06: Histopathological and molecular immune landscape and DNA damage response signatures to predict response to carboplatin and docetaxel in TNT trial TNBC cohort (2023) (0)
- Abstract 5904:TP53mutation and 5q deletion define common phenotypic changes regardless of tissue of origin (2020) (0)
- Hepatocyte growth factor pathway expression in breast cancer by race and subtype (2021) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- The Integrated Genomic L andscape of Thymic Epithelial Tumors Graphical (2018) (0)
- Abstract P1-05-11: Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas (2017) (0)
- Abstract 5240: Functional and therapeutic significance ofESR1gene fusions in breast cancer (2018) (0)
- Abstract P4-04-16: Highly variably expressed exons (HVEE) of cancer genes and survival disparity in human breast cancer (2013) (0)
- Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals TP53 Aneuploidy–driven Metabolic Reprogramming (2023) (0)
- Integrated genomic characterization of oesophageal carcinoma (2017) (0)
- Development of Biologically Based Therapies for Basal-Like Tumors (2006) (0)
- TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases (2018) (0)
- Abstract LB176: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network identifies microenvironment features as drivers of metastasis (2022) (0)
- Statistical Inference for Data Integration (2021) (0)
- Abstract 2627: Molecular analyses of histopathologic morphologic features in breast cancer (2016) (0)
- Erratum: Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes (PLoS ONE (2014) 9:1 DOI: 10.1371/annotation/e9ad5950-a048-4a44-8e26-d8b07a9d4bb8) (2014) (0)
- Abstract S4-01: An integrated genomics approach identifies novel drivers of oncogenic pathway activity in human breast cancer (2013) (0)
- Abstract PS19-03: Dna repair imbalance and immune response in breast cancer mortality disparities (2021) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- Clinical Cancer esearch ing , Diagnosis , Prognosis g Squamous Cell Carcinoma mRNA Expression Subtypes Reproducible , Clinically Important , and Correspond R ormal Cell Types (2010) (0)
- Abstract P2-03-08: Deconstructing the molecular characteristics of ER+ HER2+ early breast cancer in the POETIC trial using multiplex immunofluorescence and gene expression profiles (2023) (0)
- Muscle invasive bladder cancer: A single sample patient assay to predict molecular subtypes and benefit of neoadjuvant chemotherapy (2017) (0)
- MP16-12 INTEGRATED GENE EXPRESSION PROFILING AND TARGETED PANEL SEQUENCING TO IMPROVE TREATMENT SELECTION IN NON-MUSCLE INVASIVE BLADDER CANCER (2021) (0)
- Age at diagnosis, obesity, smoking, and molecular subtypes in muscle-invasive bladder cancer (2017) (0)
- Author Correction: Genomic basis for RNA alterations in cancer (2023) (0)
- TP53 Mutations Are Associated With Increased Pathologic Complete Response in HER2-Positive BC (2014) (0)
- Abstract 5389: Uncovering spatial relationships of the tumor microenvironment in the Carolina Breast Cancer Study (2020) (0)
- Abstract S6-1: Exploration of isoform switching and mutation expression in breast cancer by mRNA-sequencing analysis (2012) (0)
- Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434 – 5 (2019) (0)
- MOLECULAR SUBTYPES OF MUSCLE INVASIVE BLADDER CANCER ARE RELATED TO BENEFIT FROM NEOADJUVANT CHEMOTHERAPY: DEVELOPMENT OF A SINGLE SAMPLE PATIENT ASSAY: MP34‐01 (2017) (0)
- Abstract 3126: Multimodal genome-wide survey of progressing and non-progressing DCIS (2023) (0)
- Clinical Trial Update The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer (2015) (0)
- Genomic basis for RNA alterations in cancer (2020) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- Identification of mRNA isoform switching in breast cancer (2016) (0)
This paper list is powered by the following services:
Other Resources About Katherine A. Hoadley
What Schools Are Affiliated With Katherine A. Hoadley?
Katherine A. Hoadley is affiliated with the following schools:
